Hedyotis Diffusa Willd extract induces apoptosis via activation of the mitochondrion-dependent pathway in human colon carcinoma cells

International Journal of Oncology

Volumn 37, Issue 5, 2010, Pages 1331-1338

  Lin, Jiumao ^a   Chen, Youqin ^b   Wei, Lihui ^a   Chen, Xuzhen ^a   Xu, Wei ^a   Hong, Zhenfeng ^a   Sferra, Thomas J ^b   Peng, Jun ^a  

^a FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Colorectal cancer; Hedyotis Diffusa Willd; Herbal medicine; HT 29 cells; Mitochondria

Indexed keywords

CASPASE 3; CASPASE 9; HEDYOTIS DIFFUSA WILLD EXTRACT; PLANT EXTRACT; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRUCTURE; CELL VIABILITY; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DOSE RESPONSE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MEMBRANE STRUCTURE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; CELL SURVIVAL; COLONIC NEOPLASMS; DNA FRAGMENTATION; DRUGS, CHINESE HERBAL; FLOW CYTOMETRY; HEDYOTIS; HT29 CELLS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; PLANT EXTRACTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77957873646     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000785     Document Type: Article

References (33)

1. Longley DB, Allen WL and Johnston PG: Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta 1766: 184-196, 2006.
2. Johnston, PG and Kaye S: Capecitabine: a novel agent for the treatment of solid tumors. Anticancer Drugs 12: 639-646, 2001.
3. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL and Lévi F: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18: 136-147, 2000.
4. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047, 2000.
5. Boose G and Stopper H: Genotoxicity of several clinically used topoisomerase II inhibitors. Toxicol Lett 116: 7-16, 2000.
6. Park HR, Tomida A, Sato S, Tsukumo Y, Yun J, Yamori T, Hayakawa Y, Tsuruo T and Shin-ya K: Effect on tumor cells of blocking survival response to glucose deprivation. J Natl Cancer Inst 96: 1300-1310, 2004.
7. Ryoo IJ, Park HR, Choo SJ, Hwang JH, Park YM, Bae KH, Shinya K and Yoo ID: Selective cytotoxic activity of valinomycin against HT-29 human colon carcinoma cells via down-regulation of GRP78. Biol Pharm Bull 29: 817-820, 2006.
8. Newman DJ, Cragg GM and Snader KM: The influence of natural products upon drug discovery. Nat Prod Rep17: 215-234, 2000.
9. Louis Jeune MA, Kumi-Diaka J and Brown J: Anticancer activities of pomegranate extracts and genistein in human breast cancer cells. J Med Food 8: 469-475, 2005.
10. Sausville EA: Versipelostatin-unfolding an unsweetened death. J Natl Cancer Inst 96: 1266-1267, 2004.
11. Won HJ, Han CH, Kim YH, Kwon HJ, Kim BW, Choi JS and Kim KH: Induction of apoptosis in human acute leukemia Jurkat T cells by Albizzia julibrissin extract is mediated via mitochondria-dependent caspase-3 activation. J Ethnopharmacol 106: 383-389, 2006.
12. Song LR: Zhonghuabencao. Vol 61. Shanghai Science and Technology Press, Shanghai, pp433, 1999.
13. Yang JJ, Hsu HY, Ho YH and Lin CC: Comparative study on the immunocompetent activity of three different kinds of Peh-Hue-Juwa-Chi-Cao, Hedyotis diffusa, H. corymbosa and Mollugo pentaphylla after sublethal whole body x-irradiation. Phytother Res 11: 428-432, 1997.
14. Li R, Zhao HR and Lin YM: Anti-tumor effect and protective effect on chemotherapeutic damage of water soluble extracts from Hedyotis diffusa. J Chin Pharmaceu Sci 11: 54-58, 2002.
15. Adams JM and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324-1337, 2007.
16. Cory S and Adams JM: The Bcl-2 family: regulators of the cellular life-of-death switch. Nat Rev Cancer 2: 647-656, 2002.
17. Reed JC: Mechanisms of apoptosis. Am J Pathol 157: 1415-1430, 2000.
18. Vaux DL and Korsmeyer SJ: Cell death in development. Cell 96: 245-254, 1999.
19. Gross A, McDonnell JM and Korsmeyer SJ: Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899-1911, 1999.
20. Hsu YT, Wolter K and Youle RJ: Cytosol to membrane redistribution of members of the Bcl-2 family during apoptosis. Proc Natl Acad Sci USA 94: 3668-3672, 1997.
21. Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG and Youle RJ: Movement of Bax from the cytosol to mitochondria. J Cell Biol 139: 1281-1292, 1997.
22. Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M, Thompson CB and Kormeryer SJ: tBid, a membrane-targeted death ligand, oligomerizes Bak to release cytochrome c. Genes Dev 14: 2060-2071, 2000.
23. Antonsson B, Montessuit S, Lauper S, Eskes R and Martinou JC: Bax oligomerization is required for channel-forming activity in liposomes and to trigger cytochrome c release from mitochondria. Biochem J 345: 271-278, 2000.
24. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D and Reed JC: Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 95: 4997-5002, 1998.
25. Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD: The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275: 1132-1136, 1997.
26. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI and Jones DP: Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275: 1129-1132, 1997.
27. Thomenius MJ, Wang NS, Reineks EZ, Wang Z and Distelhorst CW: Bcl-2 on the endoplasmic reticulum regulates Bax activity by binding to BH3-only proteins. J Biol Chem 278: 6243-6250, 2003. (Pubitemid 36800880)
28. Antonsson B, Conti F, Ciavatta A, Montessuit S, Lewis S, Martinou I, Bernasconi L, Bernard A, Mermod JJ, Mazzei G, Maundrell K, Gambale F, Sadoul R and Martinou JC: Inhibition of Bax channel-forming activity by Bcl-2. Science 277: 370-372, 1997.
29. Youle RJ and Strasser A: The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59, 2008.
30. Yip KW and Reed JC: Bcl-2 family proteins and cancer. Oncogene 27: 6398-6406, 2008.
31. Kitada S, Pedersen IM, Schimmer AD and Reed JC: Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene 21: 3459-3474, 2002. (Pubitemid 34587716)
32. Mantymaa P, Siitonen T, Guttorm T, Saily M, Kinnula V, Savolainen ER and Koistinen P: Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol 108: 574-581, 2000. (Pubitemid 30196255)
33. + cell line KG-1. Exp Hematol 31: 815-823, 2003.